AXP Upgraded to Overweight; BIIB Stock Gains on Bullish Call

Wall Street upgrades American Express and Biogen on the same Monday, spotlighting diverging but resilient plays across financial sector analyst calls and biotech stock investment themes.

Lead

Wall Street opened Monday, July 14, 2026, with two standout calls: JPMorgan Chase elevated American Express (AXP) to Overweight from Neutral, lifting its price target to $400 from $328 — implying roughly 14% upside from the prior close of $350.58 — while Truist Securities flipped Biogen (BIIB) to Buy from Hold, setting a $235 target against a prior close of $199.15. The dual upgrades, both effective July 13, headlined a broader sweep of financial sector analyst calls that included moves on Capital One, Keysight, and NIO, and came just days before American Express's scheduled second-quarter earnings report and a landmark Alzheimer's data release from Biogen.

What Happened: AXP

JPMorgan named American Express its "preferred name in the sector," describing the card network's revenue stream as "defensive" in an environment shaped by renewed geopolitical stress following the collapse of the June 18 U.S.-Iran memorandum and a June nonfarm payroll print of just 57,000. The bank argued that AXP's concentration in affluent cardholders — whose spending and credit profiles are "relatively shielded" from macro shocks — justifies the stock's modest premium to the consumer-finance peer group.

The American Express stock upgrade arrives with AXP trading above both its 50-day moving average of $322.50 and its 200-day moving average of $333.27. Shares ticked roughly 1% higher in premarket activity following the announcement. Bank of America and Goldman Sachs have separately raised their targets to $391 and $400, respectively, both maintaining Buy-equivalent ratings, while 23 analysts now carry a consensus "Moderate Buy" with an average price target of approximately $374.

Operationally, American Express entered the upgrade cycle on firm footing. First-quarter 2026 earnings per share came in at $4.28, beating the $4.01 consensus estimate by $0.27, on revenue of $14.21 billion — up 11.4% year-over-year. Net card fees climbed 18%, representing 14.5% of total revenue, and net interest income rose 12% on an FX-adjusted basis. Cards-in-force stood at 155.9 million, with Millennial cardholders expanding 13% and Gen-Z cardholders up 38%. Management reaffirmed full-year 2026 guidance of $17.30 to $17.90 in earnings per share on 9% to 10% revenue growth. Second-quarter results are due July 24.

What Happened: BIIB

Truist analyst Srikripa Devarakonda turned bullish on BIIB stock citing an "attractive risk/reward" profile tied directly to imminent pipeline catalysts. The immediate trigger is diranersen (BIIB080), an antisense oligonucleotide targeting tau protein, whose Phase 2 CELIA study full data — clinical, biomarker, and safety — is scheduled for presentation on July 14 at the Alzheimer's Association International Conference in London. Topline results were previewed in May 2026.

Truist's probability-weighted pipeline estimates assign roughly $750 million in peak revenue to litifilimab for lupus, with a Phase 3 readout expected in Q4 2026, and approximately $500 million to felzartamab in antibody-mediated rejection, with mid-2027 data. Combined, the analyst values late-stage additions at $1.5 billion in projected 2035 revenue.

BIIB shares rose 1.3% in premarket trading to $201.63 on the upgrade. The stock has gained 13% year-to-date through July 13, though it had retreated 7.8% month-to-date ahead of the call. Truist's new $235 target implies 18% upside. Earlier in June, Needham initiated a Buy with a $255 target, pointing to an improved commercial portfolio and multiple Phase 3 readouts through 2029. Eighteen analysts now cover the stock with targets ranging from $196 to $275; the median stands near $225. Second-quarter earnings are scheduled for July 29, though Truist characterized the report as a secondary catalyst relative to pipeline events.

Strategic Context: Financial Sector Analyst Calls

Monday's round of financial sector analyst calls reflected selective, defensively oriented conviction rather than broad sector enthusiasm. HSBC simultaneously upgraded Capital One (COF) to Buy from Hold with a $229 target — citing the lender's resilient credit card portfolio — while Morgan Stanley raised Keysight Technologies (KEYS) to Overweight with a $400 target on recovered enterprise spending. Loop Capital downgraded Best Buy (BBY) to Hold in the same session, underscoring the bifurcation between quality-franchise upgrades and consumer-discretionary caution.

The macro backdrop shaping these calls features mortgage rates near 6.5%, a labor market showing slack at the margin, and the residual uncertainty of a strained U.S.-Iran ceasefire. In that context, asset-light, fee-driven franchises like American Express and pipeline-rich biotechs with near-term binary catalysts like Biogen represent two distinct forms of selective risk — one anchored in consumer resilience, the other in scientific inflection.

Biotech Stock Investment: Sector Backdrop

The dominant themes are oncology — where Revolution Medicines and others are advancing RAS-pathway therapies — and neurology, where the readout calendar for Alzheimer's drugs has intensified investor attention. Eli Lilly's oral GLP-1 orforglipron cleared its Phase 3 diabetes trial and awaits regulatory approval, reinforcing Big Pharma's appetite for pipeline acquisitions targeting mid-cap names. Biogen, with its established Leqembi franchise and the diranersen tau program, sits at the intersection of both trends.

NIH funding disruptions — 383 clinical trials terminated, affecting more than 74,000 participants — and tariff uncertainty weigh on the sector's cost base, though investors appear to be pricing pipeline optionality above near-term operational headwinds for select names.

Outlook